Table 1.

Patient characteristics by treatment arm and EGFR status determined on tumour tissue (n=250)

	EOX arm		EOX-P arm
	EGFR non-amplified (<2)	EGFR amplified (≥2)	EGFR non-amplified (<2)	EGFR amplified (≥2)
Median age (IQR)	62.6 (54.2–68.4)	63.8 (54.3–68.6)	63.2 (56.6–69.7)	63.1 (59.0–65.4)
Males (%)	97 (80.8)	7 (100)	89 (78.8)	10 (100)
Females (%)	23 (19.2)	–	24 (21.2)	–
PS 0 (%)	44 (36.7)	4 (57.1)	42 (37.2)	5 (50)
PS 1 (%)	69 (57.5)	2 (28.6)	65 (57.5)	5 (50)
PS 2 (%)	7 (5.8)	1 (14.3)	6 (5.3)	–
Locally advanced (%)	8 (6.7)	–	10 (8.9)	1 (10)
Metastatic (%)	112 (93.3)	7 (100)	103 (91.1)	9 (90)

EGFR, epidermal growth factor receptor; EOX, epirubicin, oxaliplatin, capecitabine; P, panitumumab; PS, performance status.